

Chronic Kidney Disease Therapeutic Pipeline Market Review, H2 2016

Chronic Kidney Disease Treatment Pipeline Review H2 2016

PUNE, INDIA, November 9, 2016

/EINPresswire.com/ -- [Chronic kidney](#)

[disease](#) is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity and high cholesterol.



WISE GUY
REPORTS

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com

☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>

🐦 <https://twitter.com/WiseGuyReports>

📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/731523-chronic-kidney-disease-chronic-renal-failure-pipeline-review-h2-2016>

Report Highlights

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 9, 15, 19 and 7 respectively for Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively for Chronic Kidney Disease

(Chronic Renal Failure).

Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising

pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Chronic Kidney Disease (Chronic Renal Failure) Overview 8

Therapeutics Development 9

Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure) - Overview 9

Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure) - Comparative Analysis 10

Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics under Development by Companies 11

Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics under Investigation by Universities/Institutes 14

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Chronic Kidney Disease (Chronic Renal Failure) - Products under Development by Companies 18

Chronic Kidney Disease (Chronic Renal Failure) - Products under Investigation by Universities/Institutes 21

Chronic Kidney Disease (Chronic Renal Failure) - Companies Involved in Therapeutics Development 22

Accelaron Pharma, Inc. 22

Angion Biomedica Corp. 23

Astellas Pharma Inc. 24

AstraZeneca Plc 25

Bayer AG 26

Bio-inRen 27

BioAegis Therapeutics, Inc. 28

Boehringer Ingelheim GmbH 29

Bristol-Myers Squibb Company 30

Cellmid Limited 31

Complexa, Inc. 32

CTI BioPharma Corp. 33
Evotec AG 34
F. Hoffmann-La Roche Ltd. 35
Gilead Sciences, Inc. 36
GNI Group Ltd. 37
Intercept Pharmaceuticals, Inc. 38
Lupin Limited 39
Navya Biologicals Pvt Ltd 40
Nippon Zoki Pharmaceutical Co., Ltd. 41
Novartis AG 42

Access Report @ <https://www.wiseguyreports.com/reports/731523-chronic-kidney-disease-chronic-renal-failure-pipeline-review-h2-2016> □

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/353155548>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.